News

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

A duo of experts from Feinberg School of Medicine discussed the growing role of clinical algorithms, risk stratification, and treatment considerations in managing paraneoplastic neurologic syndromes alongside cancer therapies. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 9, 2025.

Catch up on any of the neurology news headlines you may have missed over the course of April 2025, compiled all into one place by the NeurologyLive® team.

The clinical associate professor of neurology and neurosurgery at NYU Langone talked about the promise of machine learning in identifying patients at high risk for hematoma expansion to guide care. [WATCH TIME: 2 minutes]

Over long-term treatment, fenfluramine significantly reduced seizure frequency, increased seizure-free days, and improved quality of life in patients with Dravet syndrome.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the evolving role of noninvasive neuromodulation in promoting brain plasticity. [WATCH TIME: 3 minutes]

A study involving 20 patients with ALS found that longitudinal muscle MRI detected progressive atrophy and correlated with muscle strength loss, supporting its potential as a biomarker for ALS progression and clinical trials.

This episode explores treatment considerations for patients already living with SMA, emphasizing individualized goals, medical complexity, and the value of subtle clinical improvements.

Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.

The clinical professor of stroke neurology and neurocritical care at Stanford University discussed the shifting perspective on early blood pressure lowering in intracerebral hemorrhage. [WATCH TIME: 4 minutes]

Leveraging the Enroll-HD dataset, recent data revealed consistent links between antidopaminergic medication use and worsened cognitive and motor outcomes in Huntington disease.

Early findings from the ASPIRO trial showed ANPD001 was safe, well-tolerated, and led to marked improvements in motor symptoms and daily functioning.

STN-FUS provided more sustained tremor reduction, improved bradykinesia, and had a higher responder rate at 12 months, though both treatments showed comparable reductions in rigidity and motor scores.

In this episode, neurologists unpack the urgent and complex treatment decisions in newly diagnosed SMA, highlighting clinical factors, family input, and the importance of shared decision-making.

A 17-year-old with NMOSD and rituximab treatment developed PML after several relapses and secondary hypogammaglobulinemia, leading to his death 3 months after diagnosis.

The medical director for the Center for Brain injuries at Hackensack Meridian Health provided recommendations for clinicians to consider in the rehabilitation of women with TBI. [WATCH TIME: 6 minutes]

The research portfolio director at the Muscular Dystrophy Association highlighted advances in gene-targeted therapies and biomarker development as potential key drivers of progress in ALS.

Theranica's FDA-cleared, drug-free migraine device gains expanded access, more than doubling coverage to 80 million Americans as young as 8 years old who are diagnosed with migraine.

Sunny Brous, a patient advocate living with ALS, shared how her decade-long journey with the disease shaped her mission to build connection, advocate for change, and empower the ALS community.

In episode 1, panelists explore the evolving SMA treatment landscape, highlighting updated best practices shaped by new therapies, newborn screening, and international expert consensus.

Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.

The professor of neurology at the University of Buffalo talked about the clinical promise of nipocalimab and its role in broadening treatment options for patients with myasthenia gravis, including adolescents. [WATCH TIME: 4 minutes]

Capricor Therapeutics reported that it remains on track for PDUFA target action date of August 31, 2025 and noted that advisory committee meeting is to be held in advance.

Pagan offered advice on how clinicians can effectively discuss treatment and care plans with patients, especially as new treatments continue to emerge.

The award ceremony is supported by Viatris and will take place on Thursday, May 29, 2025, at the Phoenix Convention Center in Phoenix, Arizona, during the 2025 CMSC Annual Meeting.

New 24-month data further showed dose-dependent lowering of neurofilament light and trends on major end points such as cUHDRS, Total Function Capacity, and Symbol Digit Modalities Test.

Over a 4-week treatment period, daridorexant outperformed placebo on several subjective sleep and nocturia assessments, while maintaining a good safety and tolerability profile.

Pagan discussed unexpected findings from the InfusON study patient interviews that could influence how neurologists introduce CSAI therapy and how these insights, along with the latest data on MAO-B inhibitors, could shape future treatment combinations for Parkinson disease.

The expanded access program enables the collection of real-world data on the safety and efficacy of SPG302, which may support its clinical development for the treatment of amyotrophic lateral sclerosis.